Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Université de Sherbrooke

$25,000.00

Harnessing peptidase's active site to disrupt protein interaction

EF 2014-15

Résumé
Harnessing peptidase's active site to disrupt protein interactionThe interaction between the low-density lipoprotein receptor (LDLR) and the serine peptidase PCSK9 isindependent of the enzyme's catalytic activity, but is responsible for the down-regulation of this receptor. Theultimate goal of Koff Pharma is to design molecules that will decrease LDLR degradation, thus promoting LDLclearance. However, Koff needs partners to develop biochemical and functional assays to advance its R&Deffort. Our goal is to support the development of a PCSK9-LDLR interaction inhibitor. Our longstandingexpertise working with proteolytic enzymes offers an ideal opportunity for both our laboratory and Koff. Wepropose that we can use the PCSK9's catalytic site as a tethering site for pharmacophors that will disruptPCSK9-LDLR interaction. The novelty of this approach is that the catalytic site will generate selectivity andpotency, and help addressing the 'last frontier' of medicinal chemistry that is protein-protein interactions.However, as a proof of concept, we must demonstrate the feasibility of the approach, and new technologiesmust be developed. Toward this goal, we propose two aims: 1) to develop a PCSK9 enzymatic assay, and toidentify a first generation hit inhibitor; 2) to establish a PCSK9-LDLR interaction functional assay inhepatocytes. Sub-aims include the establishment of a PCSK9 expression system, the identification of apeptide-based substrate we can use to monitor its activity, and, the design of an inhibitor based on theidentified substrate. Our group has developed extensive expertise in working with proteolytic enzymes bydeveloping assays, doing enzyme biochemistry, and protein engineering. Therefore, we are perfectly suited toassist Koff. This industry-academic partnership will strengthen the capability of Koff to provide noveltreatments and our ability to perform cutting edge research in biochemistry. This project will also serve as astarting point for long-term collaboration between parties, which will lead to the training of HQPs in Canada.
Programme
Engage Grants Program
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
469488-2014
Name nom
Denault, JeanBernard
Department département
Pharmacologie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
1
Nb partie
1
Application title
Harnessing peptidase's active site to disrupt protein interaction
Keyword
NSERC
Application summary
Harnessing peptidase's active site to disrupt protein interactionThe interaction between the low-density lipoprotein receptor (LDLR) and the serine peptidase PCSK9 isindependent of the enzyme's catalytic activity, but is responsible for the down-regulation of this receptor. Theultimate goal of Koff Pharma is to design molecules that will decrease LDLR degradation, thus promoting LDLclearance. However, Koff needs partners to develop biochemical and functional assays to advance its R&Deffort. Our goal is to support the development of a PCSK9-LDLR interaction inhibitor. Our longstandingexpertise working with proteolytic enzymes offers an ideal opportunity for both our laboratory and Koff. Wepropose that we can use the PCSK9's catalytic site as a tethering site for pharmacophors that will disruptPCSK9-LDLR interaction. The novelty of this approach is that the catalytic site will generate selectivity andpotency, and help addressing the 'last frontier' of medicinal chemistry that is protein-protein interactions.However, as a proof of concept, we must demonstrate the feasibility of the approach, and new technologiesmust be developed. Toward this goal, we propose two aims: 1) to develop a PCSK9 enzymatic assay, and toidentify a first generation hit inhibitor; 2) to establish a PCSK9-LDLR interaction functional assay inhepatocytes. Sub-aims include the establishment of a PCSK9 expression system, the identification of apeptide-based substrate we can use to monitor its activity, and, the design of an inhibitor based on theidentified substrate. Our group has developed extensive expertise in working with proteolytic enzymes bydeveloping assays, doing enzyme biochemistry, and protein engineering. Therefore, we are perfectly suited toassist Koff. This industry-academic partnership will strengthen the capability of Koff to provide noveltreatments and our ability to perform cutting edge research in biochemistry. This project will also serve as astarting point for long-term collaboration between parties, which will lead to the training of HQPs in Canada.